$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

$abvc Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023087270 Filed on November 15, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$2.170K	$15.88K	$589.0K
YoY Change	-99.63%	-62.42%	65.54%
Cost Of Revenue	$139.2K	$29.61K	$265.4K
YoY Change	-47.55%	175.71%	5114.34%
Gross Profit	-$137.0K	-$13.73K	$323.6K
YoY Change	-142.35%	-143.55%	-7.74%
Gross Profit Margin	-6315.21%	-86.44%	54.94%
Selling, General & Admin	$1.752M	$1.182M	$1.961M
YoY Change	-10.63%	-63.25%	-82.26%
% of Gross Profit			605.97%
Research & Development	$72.19K	$141.3K	$1.496M
YoY Change	-95.17%	-53.74%	49.01%
% of Gross Profit			462.26%
Depreciation & Amortization	$7.580K	$7.459K	$6.440K
YoY Change	17.7%	15.43%	97.55%
% of Gross Profit			1.99%
Operating Expenses	$1.825M	$2.141M	$3.457M
YoY Change	-47.21%	-42.86%	-71.33%
Operating Profit	-$1.962M	-$2.155M	-$3.133M
YoY Change	-37.39%	-42.01%	-73.24%
Interest Expense	-$1.209M	$1.219M	-$358.8K
YoY Change	237.09%	863.07%	1202.72%
% of Operating Profit
Other Income/Expense, Net	$16.56K	-$1.214M	$63.86K
YoY Change	-74.07%	2050.52%	-87.78%
Pretax Income	-$3.154M	-$3.369M	-$3.538M
YoY Change	-10.84%	-10.69%	-68.44%
Income Tax	$175.3K	-$999.00	$962.9K
% Of Pretax Income
Net Earnings	-$3.111M	-$3.318M	-$4.864M
YoY Change	-36.04%	-10.46%	-62.12%
Net Earnings / Revenue	-143360.83%	-20885.9%	-825.81%
Basic Earnings Per Share		-$0.82
Diluted Earnings Per Share	-$0.47	-$0.82	-$0.15
COMMON SHARES
Basic Shares Outstanding	7.232M shares	3.951M shares	32.63M shares
Diluted Shares Outstanding		4.055M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$139.5K	$568.6K	$161.1K
YoY Change	-13.4%	-59.42%	-97.29%
Cash & Equivalents	$60.16K	$500.1K	$85.27K
Short-Term Investments	$79.31K	$68.52K	$75.80K
Other Short-Term Assets	$757.7K	$764.0K	$1.457M
YoY Change	-47.99%	-18.18%	-25.29%
Inventory
Prepaid Expenses
Receivables	$1.530K	$1.530K	$98.33K
Other Receivables	$747.6K	$535.0K	$513.8K
Total Short-Term Assets	$1.657M	$2.494M	$2.987M
YoY Change	-44.54%	-14.11%	-68.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.969M	$7.954M	$574.0K
YoY Change	1288.43%	1303.43%	9.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.528M	$2.677M	$842.1K
YoY Change	200.18%	228.05%	-9.72%
Other Assets	$1.416M	$1.636M	$4.291M
YoY Change	-67.0%	-66.95%	275.62%
Total Long-Term Assets	$12.84M	$14.10M	$6.868M
YoY Change	86.89%	86.05%	68.63%
TOTAL ASSETS
Total Short-Term Assets	$1.657M	$2.494M	$2.987M
Total Long-Term Assets	$12.84M	$14.10M	$6.868M
Total Assets	$14.49M	$16.59M	$9.855M
YoY Change	47.05%	58.31%	-28.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$3.696M	$3.558M	$2.910M
YoY Change	27.04%	196.15%	123.68%
Deferred Revenue	$79.50K	$79.50K	$10.99K
YoY Change	623.71%
Short-Term Debt	$899.3K	$852.5K	$1.894M
YoY Change	-52.51%	-54.32%	15.47%
Long-Term Debt Due	$569.5K
YoY Change
Total Short-Term Liabilities	$5.932M	$5.363M	$5.820M
YoY Change	1.94%	37.72%	57.61%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.654M	$0.00
YoY Change
Other Long-Term Liabilities	$429.1K	$512.8K	$799.8K
YoY Change	-46.34%	-42.58%	-29.56%
Total Long-Term Liabilities	$429.1K	$2.167M	$799.8K
YoY Change	-46.34%	142.63%	-29.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.932M	$5.363M	$5.820M
Total Long-Term Liabilities	$429.1K	$2.167M	$799.8K
Total Liabilities	$6.362M	$7.530M	$6.619M
YoY Change	-3.89%	57.29%	37.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.42M	-$62.31M	-$54.90M
YoY Change	19.15%	24.52%	42.68%
Common Stock	$7.940K	$4.823K	$32.86K
YoY Change	-75.83%	-85.22%	13.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$8.902M	$9.100M	$9.100M
YoY Change	-2.18%	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$8.388M	$9.100M	$3.099M
YoY Change
Total Liabilities & Shareholders Equity	$14.49M	$16.59M	$9.855M
YoY Change	47.05%	58.31%	-28.05%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$3.111M	-$3.318M	-$4.864M
YoY Change	-36.04%	-10.46%	-62.12%
Depreciation, Depletion And Amortization	$7.580K	$7.459K	$6.440K
YoY Change	17.7%	15.43%	97.55%
Cash From Operating Activities	-$479.5K	-$1.356M	-$461.1K
YoY Change	3.99%	164.04%	-77.58%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$21.20K	$90.00
YoY Change	-100.0%	-587.36%
Acquisitions
YoY Change
Other Investing Activities	$154.2K	-$53.16K	-$83.20K
YoY Change	-285.3%	-96.5%	100.05%
Cash From Investing Activities	$154.2K	-$74.36K	-$83.28K
YoY Change	-285.12%	-95.12%	100.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	87.42K	1.652M	-253.5K
YoY Change	-134.49%	173.66%	-105.96%
NET CHANGE
Cash From Operating Activities	-479.5K	-1.356M	-461.1K
Cash From Investing Activities	154.2K	-74.36K	-83.28K
Cash From Financing Activities	87.42K	1.652M	-253.5K
Net Change In Cash	-237.9K	220.8K	-797.9K
YoY Change	-70.19%	-115.4%	-137.02%
FREE CASH FLOW
Cash From Operating Activities	-$479.5K	-$1.356M	-$461.1K
Capital Expenditures	$0.00	$21.20K	$90.00
Free Cash Flow	-$479.5K	-$1.378M	-$461.2K
YoY Change	3.97%	170.46%	-77.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.08
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3119795	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3257912	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40700
	dei	Entity Registrant Name EntityRegistrantName	ABVC BioPharma, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0014658
	dei	Entity Address Address Line1 EntityAddressAddressLine1	44370 Old Warm Springs Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
	dei	City Area Code CityAreaCode	(510)
	dei	Local Phone Number LocalPhoneNumber	668-0881
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ABVC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7231940	shares
CY2023Q3	us-gaap	Cash Cash	500069	usd
CY2022Q4	us-gaap	Cash Cash	85265	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	620868	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1306463	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1530	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	98325	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	68521	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	75797	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	143127	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	150235	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	2493534	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2987247	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7953936	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573978	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	899817	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1161141	usd
CY2023Q3	us-gaap	Long Term Investments LongTermInvestments	2677395	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	842070	usd
CY2023Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	34256	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	117110	usd
CY2023Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	128898	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	135135	usd
CY2023Q3	us-gaap	Security Deposit SecurityDeposit	44259	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	58838	usd
CY2023Q3	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	1429016	usd
CY2022Q4	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	2838578	usd
CY2023Q3	us-gaap	Assets Assets	16591507	usd
CY2022Q4	us-gaap	Assets Assets	9579574	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	852500	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1893750	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3558213	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2909587	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	79501	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10985	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	392666	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	369314	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5363076	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5543628	usd
CY2023Q3	us-gaap	Security Deposit Liability SecurityDepositLiability	5680	usd
CY2022Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	7980	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	507151	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	791827	usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1654004	usd
CY2023Q3	us-gaap	Liabilities Liabilities	7529911	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6343435	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80662290	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	67937050	usd
CY2023Q3	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	677220	usd
CY2022Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	1354440	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62309161	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54904439	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-519123	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-517128	usd
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	9099855	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3098585	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-38259	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	137554	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9061596	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3236139	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16591507	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9579574	usd
CY2023Q3	us-gaap	Revenues Revenues	15884	usd
CY2022Q3	us-gaap	Revenues Revenues	42269	usd
	us-gaap	Revenues Revenues	150265	usd
	us-gaap	Revenues Revenues	380789	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	29614	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	10741	usd
	us-gaap	Cost Of Revenue CostOfRevenue	162831	usd
	us-gaap	Cost Of Revenue CostOfRevenue	21004	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	-13730	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	31528	usd
	us-gaap	Gross Profit GrossProfit	-12566	usd
	us-gaap	Gross Profit GrossProfit	359785	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1182093	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3216146	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3841633	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6000055	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	141310	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	305483	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	990731	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1197669	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	817740	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	225740	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1409969	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5143483	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2141143	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3747369	usd
	us-gaap	Operating Expenses OperatingExpenses	6242333	usd
	us-gaap	Operating Expenses OperatingExpenses	12341207	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2154873	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3715841	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6254899	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11981422	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	40246	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	48164	usd
	us-gaap	Interest Income Other InterestIncomeOther	147998	usd
	us-gaap	Interest Income Other InterestIncomeOther	127354	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	1218624	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	126536	usd
	us-gaap	Interest Expense InterestExpense	1390039	usd
	us-gaap	Interest Expense InterestExpense	159507	usd
CY2023Q3	abvc	Rent Income RentIncome	-3000	usd
CY2022Q3	abvc	Rent Income RentIncome	21597	usd
	abvc	Rent Income RentIncome	53900	usd
	abvc	Rent Income RentIncome	78523	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-25059	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-177	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-55625	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	17865	usd
CY2023Q3	us-gaap	Other Income OtherIncome	-7769	usd
CY2022Q3	us-gaap	Other Income OtherIncome	491	usd
	us-gaap	Other Income OtherIncome	-1174	usd
	us-gaap	Other Income OtherIncome	-59381	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1214206	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-56461	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1244940	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4854	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3369079	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3772302	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7499839	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11976568	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-999	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4222	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	80696	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-165096	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3368080	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3776524	usd
	us-gaap	Profit Loss ProfitLoss	-7580535	usd
	us-gaap	Profit Loss ProfitLoss	-11811472	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-50564	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-71660	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-175813	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-252171	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3317516	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3704864	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7404722	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11559301	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-15082	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-190019	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1995	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-426579	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3332598	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3894883	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7402727	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11985880	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.71
	us-gaap	Profit Loss ProfitLoss	-7580535	usd
	us-gaap	Profit Loss ProfitLoss	-11811472	usd
	us-gaap	Depreciation Depreciation	20949	usd
	us-gaap	Depreciation Depreciation	17364	usd
	abvc	Stock Based Compensation For Non Employees StockBasedCompensationForNonEmployees	1409969	usd
	abvc	Stock Based Compensation For Non Employees StockBasedCompensationForNonEmployees	5143483	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	38500	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	521955	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1422362	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-30564	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-35719	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-31247	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-191265	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	31909	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-27924	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-243065	usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-2300	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-189755	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	983707	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5486	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	648626	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-99306	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	68516	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-155697	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	58402	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3756385	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6937322	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21201	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	119603	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	493158	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	1518793	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-514359	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1638396	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1050000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3917425	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2429028	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1352512	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	350000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3831540	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4267425	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168413	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-286775	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-270791	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4595068	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1391728	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6565215	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1120937	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1970147	usd
	us-gaap	Interest Paid Net InterestPaidNet	27525	usd
	us-gaap	Interest Paid Net InterestPaidNet	161741	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8870342	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4466325	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3663863	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	451480	usd
	us-gaap	Profit Loss ProfitLoss	-8034948	usd
	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-236560	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9180502	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	253500	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	225740	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3776524	usd
CY2022Q3	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-190019	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5693199	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3236139	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	140749	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1729028000000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	451480	usd
	us-gaap	Profit Loss ProfitLoss	-4212455	usd
	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	17077	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1362018	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1050000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	592000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	7400000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1814800	usd
CY2023Q3	abvc	Issuance Of Prefunded Warrant IssuanceOfPrefundedWarrant	700000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-699800	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	225740	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3368080	usd
CY2023Q3	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-15082	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9061596	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3368080	usd
	us-gaap	Profit Loss ProfitLoss	-7580535	usd
	abvc	Working Capital Deficit WorkingCapitalDeficit	2869542	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3756385	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Reclassifications of Prior Year Presentation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Certain prior year unaudited consolidated balance sheet and unaudited consolidated cash flow statement amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock
CY2016Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	360000000	shares
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On July 25, 2023, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock.
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	500069	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85265	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	620868	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1306463	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company performs ongoing credit evaluation of our customers and requires no collateral. An allowance for doubtful accounts is provided based on a review of the collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit losses may differ from our estimates.</span></p>
	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	0.9976	pure
CY2022	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	0.7189	pure
	abvc	Total Revenues Percentage TotalRevenuesPercentage	0.8119	pure
	abvc	Total Revenues Percentage TotalRevenuesPercentage	0.7918	pure
	abvc	Schedule Of Ownership Percentages Of Investee Table Text Blocks ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks	<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Ownership percentage</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accounting</span></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name of related party</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">treatments</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Braingenesis Biotechnology Co., Ltd.</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.22</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.22</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost Method</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Genepharm Biotech Corporation</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">BioHopeKing Corporation</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost Method</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">BioFirst Corporation</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">23.53</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity Method</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Rgene Corporation</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28.85</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28.85</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity Method</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
	abvc	Share Of Equity Method Investee Losses ShareOfEquityMethodInvesteeLosses		usd
	abvc	Labour Pension Fund Percentage LabourPensionFundPercentage	0.06	pure
	abvc	Percentage Of Monthly Contributions PercentageOfMonthlyContributions	0.06	pure
CY2023Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2566	usd
CY2022Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	3302	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	7825	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	9948	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2023Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2022Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	817740	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	225740	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1409969	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5143483	usd
	abvc	Beneficial Conversion Feature BeneficialConversionFeature	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Beneficial Conversion Feature</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</span></p>
	abvc	Defined Benefit Plan Funded Percentages DefinedBenefitPlanFundedPercentages	0.50	pure
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	852500	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1893750	usd
CY2023Q3	abvc	Principal Amount principalAmount	7500000	twd
CY2023Q3	abvc	Principal Amount principalAmount	232500	usd
	abvc	Debt Instrument I Effectiventerest Rate Percentage DebtInstrumentIEffectiventerestRatePercentage	0.0285	pure
CY2019Q1	us-gaap	Debt Instrument Repurchased Face Amount DebtInstrumentRepurchasedFaceAmount	1000000	usd
	abvc	Milestone Payments Royalty Percentage MilestonePaymentsRoyaltyPercentage	0.12	pure
	abvc	Collaborative Agreements Description CollaborativeAgreementsDescription	In addition to the total of NT$50 million, approximately equivalent to $1.64 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.
	abvc	Co Dev Agreement Description CoDevAgreementDescription	the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.64 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.
CY2022Q2	abvc	Eligible To Receive Payments EligibleToReceivePayments	3000000	usd
CY2022Q2	abvc	Milestone Regulatory Payment Amount Period MilestoneRegulatoryPaymentAmountPeriod	P3Y
CY2023Q3	us-gaap	Loans Payable LoansPayable	1000000	usd
	abvc	Working Capital Convertible Loan Percentage WorkingCapitalConvertibleLoanPercentage	0.05	pure
	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note.
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11264530	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3878435	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3310594	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3304457	usd
CY2023Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	7953936	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	573978	usd
CY2023Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	37000000	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	7400000	usd
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	370000	shares
CY2023Q3	us-gaap	Share Price SharePrice	20
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7459	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6462	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20949	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17364	usd
CY2023Q3	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	803205	usd
CY2022Q4	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	842070	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	2677395	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	842070	usd
CY2022Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	618150	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.2885	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.2885	pure
CY2023Q1	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	3175000	usd
CY2023Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	1.05
CY2023Q1	us-gaap	Shares Issued SharesIssued	5291667	shares
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Exercise Price DeferredCompensationArrangementWithIndividualExercisePrice	1.05
	abvc	Percentage Of Average Amount PercentageOfAverageAmount	0.90	pure
	abvc	Percentage Of Cash Permium PercentageOfCashPermium	0.05	pure
CY2023Q3	abvc	Percentage Of Outstanding Principal Amount PercentageOfOutstandingPrincipalAmount	1.15	pure
CY2023Q3	us-gaap	General Partners Capital Account GeneralPartnersCapitalAccount	12500000	usd
CY2023Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	3.5
CY2019Q1	us-gaap	Debt Instrument Interest Rate Increase Decrease DebtInstrumentInterestRateIncreaseDecrease	0.05	pure
CY2020Q2	abvc	Received Loan Amount ReceivedLoanAmount	350000	usd
CY2020Q4	abvc	Received Loan Amount ReceivedLoanAmount	350000	usd
CY2021Q4	abvc	Principal Amount principalAmount	650000	usd
CY2022	abvc	Outstanding Balance OutstandingBalance	1000000	usd
CY2023Q3	us-gaap	Other Receivables OtherReceivables	624373	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	757343	usd
	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	1900	usd
CY2022	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	307788	usd
CY2023Q3	abvc	Due From Other Related Parties Noncurrent Amount DueFromOtherRelatedPartiesNoncurrentAmount	930396	usd
CY2022Q4	abvc	Due From Other Related Parties Noncurrent Amount DueFromOtherRelatedPartiesNoncurrentAmount	865477	usd
CY2022Q2	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.05	pure
CY2022Q2	abvc	Working Capital Percentage WorkingCapitalPercentage	0.064	pure
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-165096	usd
	abvc	Share Of Equity Method Investee Losses ShareOfEquityMethodInvesteeLosses		usd
	abvc	Description Of Conversion Price DescriptionOfConversionPrice	The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.
	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	500000	usd
	us-gaap	Accounts Receivable Noncurrent Accrued Interest Writeoff AccountsReceivableNoncurrentAccruedInterestWriteoff	32518	usd
CY2022	us-gaap	Accounts Receivable Noncurrent Accrued Interest Writeoff AccountsReceivableNoncurrentAccruedInterestWriteoff	13819	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	507000	usd
CY2023Q3	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.065	pure
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	107615	usd
CY2022	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	112822	usd
	abvc	Schedule Of Related Party Transactions Amount Due To Related Party ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty	<span style="font-family: Times New Roman, Times, Serif">Amount due to related parties consisted of the following as of the periods indicated:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">BioFirst Corporation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">315,947</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">188,753</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">The Jiangs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,789</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Due to shareholders</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">144,460</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">151,450</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">480,196</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">359,992</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>
CY2023Q3	abvc	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	480196	usd
CY2022Q4	abvc	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	359992	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	315947	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	188753	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	9327	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	24400	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2023Q3	abvc	Outstanding Principal And Accrued Interests OutstandingPrincipalAndAccruedInterests	144460	usd
CY2022Q4	abvc	Outstanding Principal And Accrued Interests OutstandingPrincipalAndAccruedInterests	151450	usd
CY2023Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	5015	usd
CY2022Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	5208	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	15082	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	15922	usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1600	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1600	usd
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	80696	usd
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-166696	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	80696	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-166696	usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	80696	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	679428	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	709961	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5713161	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5866623	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	213482	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	213482	usd
CY2023Q3	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	213482	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	213482	usd
CY2023Q3	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	6392589	usd
CY2022Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	6576584	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6358333	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6459474	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	34256	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	117110	usd
CY2022Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	4296763	usd
CY2022Q1	abvc	Unrestricted Common Shares UnrestrictedCommonShares	1306007	shares
CY2022Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.29
CY2022Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	2000000	shares
CY2022Q2	abvc	Gross Proceeds GrossProceeds	4220000	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	556075	usd
CY2022Q2	us-gaap	Credit Derivative Term1 CreditDerivativeTerm1	P5Y
CY2022Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	2000000	shares
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2.45	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	223411	shares
CY2023Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	3704167	usd
CY2023Q3	us-gaap	Investment Sold Not Yet Purchased Balance Shares InvestmentSoldNotYetPurchasedBalanceShares	614912	shares
CY2023Q3	us-gaap	Investment Sold Not Yet Purchased Balance Principal Amount InvestmentSoldNotYetPurchasedBalancePrincipalAmount	1814800	usd
CY2023Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	3.5
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	300000	shares
CY2023Q3	abvc	Purchase Price Per Share PurchasePricePerShare	3.5
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	545182	shares
CY2020Q4	abvc	Conversion Price ConversionPrice	2
CY2020Q4	abvc	Consulting Fees ConsultingFees	1090361	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	545182	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1280002	shares
CY2021Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	761920	shares
CY2022Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0279	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8386	pure
CY2022	abvc	Fair Value Of Options Granted FairValueOfOptionsGranted	2.79	usd
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	0	usd
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	96875	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	87367	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	288751	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	261494	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	288751	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	261494	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y14D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M23D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0153	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0149	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	96585	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	400432	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	350693	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	56916	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	904626	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4809	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	899817	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001173313

Files In Submission

Name	View Source	Status
0001213900-23-087270-index-headers.html	Edgar Link	pending
0001213900-23-087270-index.html	Edgar Link	pending
0001213900-23-087270.txt	Edgar Link	pending
0001213900-23-087270-xbrl.zip	Edgar Link	pending
abvc-20230930.xsd	Edgar Link	pending
f10q0923ex10-40_abvcbio.htm	Edgar Link	pending
f10q0923ex10-41_abvcbio.htm	Edgar Link	pending
f10q0923ex31-1_abvcbio.htm	Edgar Link	pending
abvc-20230930_cal.xml	Edgar Link	unprocessable
abvc-20230930_def.xml	Edgar Link	unprocessable
abvc-20230930_lab.xml	Edgar Link	unprocessable
abvc-20230930_pre.xml	Edgar Link	unprocessable
f10q0923ex31-2_abvcbio.htm	Edgar Link	pending
f10q0923ex32-1_abvcbio.htm	Edgar Link	pending
f10q0923ex32-2_abvcbio.htm	Edgar Link	pending
f10q0923_abvcbio.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
f10q0923_abvcbio_htm.xml	Edgar Link	completed
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

2023 Q4 Form 10-Q Financial Statement

#000121390023087270 Filed on November 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC ABVC BIOPHARMA, INC. Stock $abvc

2023 Q4 Form 10-Q Financial Statement

#000121390023087270 Filed on November 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc